However, enthusiasm for applying TGFβ inhibitors as a therapeutic strategy to treat metastatic bone disease including mCRPC is limited because of the pleiotropic and often opposing roles TGFβ plays in normal and cancer cell biology5, 24, 25, 48, 49. The gene discussed is TGFB1; the disease is cancer.